Dataset Information

Clinical effects of probiotic or azithromycin as an adjunct to scaling and root planning in the treatment of stage III periodontitis: a pilot randomized controlled clinical trial.

ABSTRACT:

Background

The aim of this triple-blind placebo-controlled parallel-arm randomized clinical trial was to evaluate the clinical effects of Lactobacillus rhamnosus SP1 or azithromycin as an adjunct to scaling and root planing (SRP) in patients with stage III periodontitis.

Methods

Forty-seven systemically healthy participants with stage III periodontitis were recruited. Following SRP, the participants were randomly assigned to one of three treatment modalities; (1) placebo (n?=?15), (2) probiotics (n?=?16) and (3) antibiotics-azithromycin (n?=?16). The participants were monitored at baseline, 3, 6, 9 and 12 months after therapy. Probing pocket depth (PPD), bleeding on probing (BOP), clinical attachment loss (CAL) and plaque accumulation (PI) were evaluated.

Results

All 47 participants completed the study. At 12 months, all groups showed significant improvements of PPD and PI (p?ConclusionThe use of probiotics or azithromycin as an adjunct to SRP failed to provide additional benefits in the treatment of stage III periodontitis. The benefits of these two treatment regimes as an adjunct to SRP remain unclear.

Trial registration

NCT02839408, 10/28/2017, Clinicaltrial.gov.

SUBMITTER: Morales A

PROVIDER: S-EPMC7792194 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Clinical effects of probiotic or azithromycin as an adjunct to scaling and root planning in the treatment of stage III periodontitis: a pilot randomized controlled clinical trial.

Morales Alicia A Contador Rafael R Bravo Joel J Carvajal Paola P Silva Nora N Strauss Franz-Josef FJ Gamonal Jorge J

BMC oral health 20210107 1

<h4>Background</h4>The aim of this triple-blind placebo-controlled parallel-arm randomized clinical trial was to evaluate the clinical effects of Lactobacillus rhamnosus SP1 or azithromycin as an adjunct to scaling and root planing (SRP) in patients with stage III periodontitis.<h4>Methods</h4>Forty-seven systemically healthy participants with stage III periodontitis were recruited. Following SRP, the participants were randomly assigned to one of three treatment modalities; (1) placebo (n = 15), ...[more]

PMID: 33413320

Similar Datasets

Project description:The aim of the studyTo evaluate the effect of curcumin gel combined with scaling and root planing (SRP) on salivary procalcitonin in periodontitis treatment.Materials and methodsseventy patients were selected from the Department of Oral Medicine and Periodontology, Faculty of Dentistry, Mansoura University, and sixteen patients were excluded. Patients in groups II and III included stage II grade A periodontitis. The participants were classified into three groups: group I as a negative control group (individuals with healthy gingiva), group II (SRP) were treated with SRP, and group III (curcumin gel) which was applied weekly for four weeks after SRP. Clinical indices (plaque index (PI), gingival index (GI), clinical attachment level (CAL), and probing depth (PD)) and saliva samples for procalcitonin (PCT) assessment using an enzyme-linked immunosorbent assay (ELISA) test were collected and measured at both baselines and after six weeks.ResultsThis randomized controlled clinical trial registered on ClinicalTrials.gov (NCT05667376) and first posted at 28/12/2022 included Fifty-four patients (20 male; 34 female). Regarding the age and sex distribution, there was no statistically significant difference between the three studied groups (p > 0.05). There was no significant statistical difference regarding PI, GI, PPD, and CAL between group II and group III at baseline p (> 0.05). However, there was a significant statistical difference regarding the clinical parameters at baseline of both group II and group III as compared to group I (p ≤ 0.05). At six weeks after treatment, group III showed greater improvement in the PI, PD, and CAL as opposed to group II (p ≤ 0.05). Regarding PCT values, at baseline, there wasn't a statistically significant difference between group II and group III (p > 0.05). However, there was a significant statistical difference between group II, group III, and group I (p ≤ 0.05). At six weeks after treatment, there was a statistically significant decrease in PCT levels of both group II and III (p ≤ 0.05).ConclusionThe application of curcumin gel was found to have a significant effect on all clinical indices as opposed to SRP.

Project description:The aim of this systematic review was to evaluate clinical and microbiological outcomes with the use of azithromycin as an adjunct to non-surgical subgingival professional mechanical plaque removal (PMPR) in the treatment of grade C periodontitis. Online database searches using high-level MeSH terms in a PICO structure were conducted along with hand-searching of relevant periodontal journals. Titles and abstracts of identified studies were independently reviewed by both authors and the full texts of studies meeting the inclusion criteria were independently reviewed. In total, 122 studies were identified through searches, of which 6 were included in the qualitative analysis and 4 in the meta-analysis. Three studies included in the meta-analysis were deemed at low risk of bias and 1 at serious risk. There were conflicting results on whether azithromycin reduced the number of subgingival pathogens or detectable subgingival Aggregatibacter actinomycetemcomitans between the included studies. The meta-analysis revealed a statistically significant probing depth reduction difference in favour of azithromycin compared to the control at 3 months (weighted mean difference [WMD]=-0.39 mm; 95% confidence interval [CI], -0.66 to -0.13 mm; I²=0%) and 12 months (WMD=-1.32 mm; 95% CI, -1.71 to -0.93 mm; I²=0%). The clinical attachment level change was also statistically significant in favour of azithromycin compared to the control at 3 months (WMD=-0.61 mm; 95% CI, -1.13 to -0.10 mm; I²=71%) and 12 months (WMD=-0.88 mm; 95% CI, -1.32 to -0.44 mm; I²=0%). Based upon these results, azithromycin offers additional improvements in some clinical parameters when used in conjunction with subgingival PMPR in patients with aggressive periodontitis over control groups. These improvements appear to be maintained for up to 12 months after treatment completion. However, due to a lack of well-designed studies, the conclusions that can be drawn from the available evidence are limited. Trial Registration: International Prospective Register of Systematic Reviews Identifier: CRD42020168195.

Project description:ObjectivePeriodontitis progression is related to the dynamic dysbiosis of oral microbiome. We identified the dominant bacteria and the potential pathway in young women with stage-III periodontitis.Materials and methodsSamples of subgingival plaque were collected from 26 young women with periodontitis (20 with stage-I and 6 with stage-III). Using 16S rRNA-sequencing, we determined the variation in oral bacterial communities of the two groups, and identified the dominant bacteria of each group. We used the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to evaluate the signaling pathways related to the difference in oral bacterial composition. The role of the dominant bacteria of stage-III periodontitis was investigated in vivo and in vitro using an endoplasmic reticulum stress inhibitor.ResultsYoung women with stage-I periodontitis had higher values for the Chao1 Index, Observed Species and Phylogenetic Diversity Whole Tree Index than those for women with stage-III periodontitis. β-diversity analyses revealed that samples could be divided into different groups according to the periodontitis stage. The most representative biomarkers of stage-III periodontitis in young women were bacteria of the phylum Bacteroidetes, its order, family and genera Bacteroidales, Prevotellaceae and Prevotella. The KEGG database revealed that the change in oral bacterial composition of young women with stage-III periodontitis may be related to protein processing in an endoplasmic reticulum pathway. Salubrinal (an endoplasmic reticulum stress regulator) controlled expression of Runx2, Col1a1, Ocn in mouse bone-marrow mesenchymal cells. Salubrinal administration showed that moderate endoplasmic reticulum stress inhibited alveolar bone loss in periodontitis induced by Prevotella intermedia lipopolysaccharide.ConclusionDifferences between periodontitis stages were noted and bacteria of Prevotella species were abundant in young women with stage-III periodontitis. This phenomenon was related to protein processing in an endoplasmic reticulum pathway.

Dataset Information

Clinical effects of probiotic or azithromycin as an adjunct to scaling and root planning in the treatment of stage III periodontitis: a pilot randomized controlled clinical trial.

Background

Methods

Results

Trial registration

Publications

Clinical effects of probiotic or azithromycin as an adjunct to scaling and root planning in the treatment of stage III periodontitis: a pilot randomized controlled clinical trial.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets